Global viscosupplementation market set to reach $9.15 billion by 2033 with CAGR of 8.10%

From GlobeNewswire: 2024-06-14 14:00:00

The global viscosupplementation market is set to grow from USD 4.20 billion in 2023 to USD 9.15 billion by 2033, with a CAGR of 8.10%. Viscosupplementation involves injecting hyaluronic acid to alleviate joint pain associated with osteoarthritis. Factors like aging population, obesity, and sedentary lifestyles are driving market growth, despite barriers like high production costs and regulatory challenges. The three-injection segment is expected to dominate the market due to its effectiveness in treating osteoarthritis, while the osteoarthritis segment will have the largest market share. North America is projected to lead the market, followed by Asia Pacific due to rising cases of knee osteoarthritis. Major players in the market include Sanofi, Bioventus, and Johnson and Johnson. In recent developments, Anika Therapeutics met the primary endpoint of its Phase III study for Cingal, a drug for knee osteoarthritis, and Seikagaku Corporation launched HyLink, a single-injection viscosupplement for knee osteoarthritis treatment in Taiwan. The viscosupplementation market is segmented based on dosage, arthritis type, and end user, with regional analysis covering North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. Key insights and competitive analysis are provided to help industry players make informed decisions.



Read more at GlobeNewswire: Global Viscosupplementation Market Size To Worth USD 9.15